ALKS earnings: real EPS beat/miss history, analyst consensus Buy, P/E 56.54. Updated 2026-07-23.
Alkermes (ALKS) Research Hub
Alkermes (ALKS) trades on NASDAQ, IE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 45.97 USD (+1.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 56.54, market cap 8.75B. This hub links to the full technical, earnings and options research available for ALKS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IE |
| Last close | 45.97 USD (+1.26%) |
| 52-week range | 43.34 USD – 55.67 USD |
| Trend regime | Range |
| 14-day RSI | 30.3 (Bearish) |
| Trailing P/E | 56.54 |
| Market cap | 8.75B |
| Dividend yield | 0.00% |
Available research for ALKS
Covered Call on ALKS: how it works, illustrative setup around the real 45.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALKS: how it works, illustrative setup around the real 45.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALKS: how it works, illustrative setup around the real 45.97 USD price, max profit/loss, breakeven and when to use it. Educational.
ALKS technical analysis: range, last 45.97 USD, RSI 30.3, 52w range 43.34 USD–55.67 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ALKS in?
Alkermes (ALKS) is classified under Healthcare (Biotechnology), listed on NASDAQ, IE.
Is ALKS in an uptrend or downtrend?
As of 2026-09-11, ALKS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALKS's trailing P/E ratio?
ALKS's trailing P/E is 56.54, with a market cap of 8.75B. See the earnings research page for full valuation detail.